<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01830790</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00042897</org_study_id>
    <nct_id>NCT01830790</nct_id>
  </id_info>
  <brief_title>Effects of Sildenafil on Choroidal Thickness in AMD</brief_title>
  <official_title>Effects of Sildenafil on Choroidal Thickness in Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Choroidal thinning has been hypothesized to partake in the pathogenesis of age-related
      macular degeneration (AMD), but it is not known if increasing choroidal thickness may
      potentially alter the disease course. Past studies have shown that a single dose of the
      phosphodiesterase type-5 inhibitor sildenafil citrate can increase choroidal thickness in
      young healthy patients. The investigators hypothesize that sildenafil may also increase
      choroidal thickness in eyes with AMD and perhaps potentially reduce AMD progression.
      Alternatively, if sildenafil has minimal effect on choroidal thickness in eyes in patients
      with AMD, such results may suggest that choroidal vascular compliance or stiffness is reduced
      in this condition. Patients seen at the Duke Eye Center with a diagnosis of AMD or
      age-matched control subjects with no macular pathology will be administered a single 100mg
      oral dose of sildenafil citrate (ViagraÂ®; Pfizer), and undergo EDI-OCT imaging before and
      after treatment. Images obtained will be used to measure choroidal thickness, as well as
      central macular thickness (CMT) and macular volume (MV). Choroidal thickness changes after a
      single-dose sildenafil treatment in AMD patients will be compared with age-matched control
      subjects using standard statistical methods. By also correlating choroidal thickness changes
      with functional (visual acuity) and anatomical (CMT &amp; MV) changes, the investigators hope to
      further their understanding of the choroid's role in aging and AMD pathogenesis. The safety
      of a single dose of sildenafil citrate will be addressed by excluding any patients with risk
      factors or using medications that are contraindicated for sildenafil as determined by careful
      informed consent and a study questionnaire.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inadequate support to complete recruitment/data analysis.
  </why_stopped>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Choroidal Thickness as Assessed on Enhanced-Depth Imaging Optical Coherence Tomography (EDI-OCT)</measure>
    <time_frame>Baseline, 1 hour, and 3 hours post-treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Central Foveal Thickness as Assessed by Optical Coherence Tomography (OCT)</measure>
    <time_frame>Baseline, 1hour, and 3 hours post-treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy individuals &gt;65 years old without ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMD patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Age-related macular degeneration (AMD) patients &gt;65 years old without other ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil citrate</intervention_name>
    <description>Single dose of 100mg Sildenafil citrate</description>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>AMD patients</arm_group_label>
    <other_name>Viagra</other_name>
    <other_name>Revatio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  has been diagnosed with AMD (362.50-52) or healthy controls as detailed above

          -  at least 65 years of age

          -  capable and willing to provide consent

        Exclusion Criteria:

          -  History of previous photodynamic therapy (PDT), intravitreal corticosteroid injection,
             macular focal laser photocoagulation, panretinal photocoagulation, ocular ionizing
             irradiation, transpupillary thermotherapy, or any vitreoretinal surgeries

          -  History of central serous chorioretinopathy, polypoidal choroidal vasculopathy,
             uveitis, or diabetic retinopathy

          -  History of amblyopia, glaucoma, retinal detachment, retinal dystrophy, ocular trauma,
             ocular tumor, proliferative retinopathy, or epiretinal membrane with distortion of
             central macula

          -  History of myopia of more than 6 diopters (D) spherical equivalent

          -  History of uncontrolled diabetes or hypertension

          -  Current use of oral phosphodiesterase type 5 inhibitors (including sildenafil,
             avanafil, lodenafil, mirodenafil, tadalafil, vardenafil, udenafil, zaprinast)

          -  Current use of systemic corticosteroids

          -  Any contraindication to sildenafil use, including history of cardiovascular disease or
             stroke, hepatic cirrhosis (Child-Pugh A and B), severe renal impairment (creatinine
             clearance &lt;30mL/min), anatomical deformation of the penis (such as angulation,
             cavernosal fibrosis, or Peyronie's disease), disorders predisposing to priapism (e.g.
             sickle cell anemia, multiple myeloma, or leukemia), or current use of organic
             nitrates, alpha-blockers, or potent cytochrome P450 3A4 inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon Fekrat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Eye Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Eye Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2013</study_first_submitted>
  <study_first_submitted_qc>April 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2013</study_first_posted>
  <results_first_submitted>April 29, 2015</results_first_submitted>
  <results_first_submitted_qc>April 29, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 14, 2015</results_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Healthy Controls</title>
          <description>Healthy individuals &gt;65 years old without ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness
Sildenafil citrate: Single dose of 100mg Sildenafil citrate</description>
        </group>
        <group group_id="P2">
          <title>AMD Patients</title>
          <description>Age-related macular degeneration (AMD) patients &gt;65 years old without other ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness
Sildenafil citrate: Single dose of 100mg Sildenafil citrate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Controls</title>
          <description>Healthy individuals &gt;65 years old without ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness
Sildenafil citrate: Single dose of 100mg Sildenafil citrate</description>
        </group>
        <group group_id="B2">
          <title>AMD Patients</title>
          <description>Age-related macular degeneration (AMD) patients &gt;65 years old without other ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness
Sildenafil citrate: Single dose of 100mg Sildenafil citrate</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Choroidal Thickness as Assessed on Enhanced-Depth Imaging Optical Coherence Tomography (EDI-OCT)</title>
        <time_frame>Baseline, 1 hour, and 3 hours post-treatment</time_frame>
        <population>Study was terminated early due to inadequate support to complete recruitment/data analysis. No outcome measure data was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy individuals &gt;65 years old without ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness
Sildenafil citrate: Single dose of 100mg Sildenafil citrate</description>
          </group>
          <group group_id="O2">
            <title>AMD Patients</title>
            <description>Age-related macular degeneration (AMD) patients &gt;65 years old without other ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness
Sildenafil citrate: Single dose of 100mg Sildenafil citrate</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Choroidal Thickness as Assessed on Enhanced-Depth Imaging Optical Coherence Tomography (EDI-OCT)</title>
          <population>Study was terminated early due to inadequate support to complete recruitment/data analysis. No outcome measure data was collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Central Foveal Thickness as Assessed by Optical Coherence Tomography (OCT)</title>
        <time_frame>Baseline, 1hour, and 3 hours post-treatment</time_frame>
        <population>Study was terminated early due to inadequate support to complete recruitment/data analysis. No outcome measure data was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy individuals &gt;65 years old without ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness
Sildenafil citrate: Single dose of 100mg Sildenafil citrate</description>
          </group>
          <group group_id="O2">
            <title>AMD Patients</title>
            <description>Age-related macular degeneration (AMD) patients &gt;65 years old without other ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness
Sildenafil citrate: Single dose of 100mg Sildenafil citrate</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Central Foveal Thickness as Assessed by Optical Coherence Tomography (OCT)</title>
          <population>Study was terminated early due to inadequate support to complete recruitment/data analysis. No outcome measure data was collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Healthy Controls</title>
          <description>Healthy individuals &gt;65 years old without ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness
Sildenafil citrate: Single dose of 100mg Sildenafil citrate</description>
        </group>
        <group group_id="E2">
          <title>AMD Patients</title>
          <description>Age-related macular degeneration (AMD) patients &gt;65 years old without other ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness
Sildenafil citrate: Single dose of 100mg Sildenafil citrate</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated early due to inadequate support to complete recruitment/data analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sharon Fekrat: Associate Professor of Ophthalmology</name_or_title>
      <organization>Duke University</organization>
      <phone>(919) 681-0341</phone>
      <email>Sharon.Fekrat@dm.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

